IPH — Innate Pharma SA Balance Sheet
0.000.00%
- €161.09m
- €169.39m
- €12.62m
Annual balance sheet for Innate Pharma SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | PRESS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 152 | 120 | 101 | 92.5 | 80.8 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 13.9 | 13.5 | 31 | 55.6 | 1.64 |
| Prepaid Expenses | |||||
| Total Current Assets | 173 | 138 | 140 | 148 | 85.7 |
| Net Property, Plant And Equipment | 11.7 | 10.2 | 8.54 | 6.32 | 5.13 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 307 | 267 | 208 | 175 | 111 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 45.5 | 79.9 | 41.3 | 39.6 | 33 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 151 | 160 | 154 | 123 | 102 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 156 | 107 | 54.2 | 51.9 | 8.83 |
| Total Liabilities & Shareholders' Equity | 307 | 267 | 208 | 175 | 111 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |